The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

November 16, 2016 • By Megan L. Krause, MD, Vinicius Domingues, MD & Donald Miller, PharmD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Arnon Thongkonghan/shutterstock.com

Arnon Thongkonghan/shutterstock.com

Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the cornea, ciliary body, lens and retina.1 Corneal deposits, fortunately, rarely affect vison.2 However, the concern of retinal toxicity and the need for monitoring must be reviewed with patients prior to and during its use.2,3

You Might Also Like
  • Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine
  • Hydroxychloroquine Retinopathy Still Alive and Well
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
Explore This Issue
November 2016

Monitoring is intended to identify separate ocular disease that would interfere with identifying changes or baseline retinal disease that could increase hydroxychloroquine’s risk, as well as to detect the earliest changes related to hydroxychloroquine. The concern with retinal toxicity is that this may be irreversible and may progress even after hydroxychloroquine discontinuation. Identifying toxicity prior to changes affecting the fundus limits potential for further deterioration.4 Despite this, a significant proportion of individuals receive hydroxychloroquine without eye examinations.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Prevalence

Estimates of prevalence are variable among studies, with differences likely representing the increasing availability of more sensitive testing and case ascertainment by the studies. Further, the impairment experienced by patients was variable. Initial studies demonstrated the risk as low as 0.5% and no events of retinal toxicity when dosing was below 6.5 mg/kg/day of ideal body weight.6 Further a prospective cohort demonstrated incidence of 0.5% in patients all treated with less than 6.5 mg/kg/day with no events occurring until after six years of treatment.7

Wolfe et al, in a study of patient-reported toxicity with review of medical records by experts, identified overall prevalence as 0.65%. However, the probability of toxicity was 0.29% after five years and further increased after 10 years (1%) and 15 years (2.1%).8 In a study published in 2014 by Melles and Marmor that included only patients who had been assessed with visual field examination or Spectral Domain-Optical Coherence Tomography (SD-OCT), the prevalence was 7.5%.9

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Fortunately, thus far, studies have not identified clear risk to children who had an in utero exposure.10 In certain scenarios particularly systemic lupus erythematosus, hydroxychloroquine is felt to be an important treatment option for pregnant women.11

Ideal Body Weight Vs. Real Body Weight

In terms of daily dose, initial studies emphasized a cut-off of 6.5 mg/kg of ideal body weight in terms of toxicity risk.12 However, due to the typical dosing of either 200 or 400 mg of hydroxychloroquine, it is rare for individuals to receive higher than this cut-off. More recent studies suggest that real body weight predicts retinal toxicity better than ideal body weight.9 Further, a cut-off of 5 mg/kg/day based on real body weight has been proposed.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions Tagged With: eye, HYDROXYCHLOROQUINE, ocular disease, ophthalmalogist, patient care, retinal toxicity, Rheumatic Disease, rheumatologist, risk, therapy, Treatment, visionIssue: November 2016

You Might Also Like:
  • Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine
  • Hydroxychloroquine Retinopathy Still Alive and Well
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
  • Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.